Business Context and Reporting Period
GRI Bio, Inc. filed this Current Report on Form 8-K regarding a corporate action effective January 29, 2024. GRI Bio is an emerging growth company whose common stock trades on The Nasdaq Capital Market under the symbol “GRI.”
Material Corporate Action
- The company filed an amendment to its amended and restated certificate of incorporation to implement a 1-for-7 reverse stock split of its common stock.
- The reverse stock split became effective at 4:01 p.m. Eastern Time on January 29, 2024, and post-split trading began at the market open on January 30, 2024.
- Every seven issued and outstanding shares were automatically converted into one share. The par value remained $0.0001 per share.
- Proportionate adjustments apply to the exercise prices and share quantities of outstanding options, warrants, convertible securities, and equity incentive plans.
- The number of authorized common shares was not changed.
- Fractional shares will be settled in cash based on the fractional interest multiplied by the January 29, 2024 closing sales price, as adjusted for the reverse split.
- The common stock continues to trade under the symbol “GRI.” The new CUSIP is 3622AW 205.
Financial Metrics and Liquidity
This filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other operating financial metrics.
Outlook, Risks, and Unusual Items
The filing provides no financial guidance or management outlook. The principal unusual item is the 1-for-7 reverse stock split, which may affect per-share trading data, outstanding equity awards, warrants, convertible securities, and the number of shares outstanding. The filing does not state the post-split share count or quantify the expected cash payments for fractional shares.
Important Facts to Verify
- Confirm the post-split share count and any resulting changes in the company’s equity capitalization.
- Verify adjusted exercise prices and share quantities for options, warrants, convertible securities, and incentive plans.
- Review the Certificate of Amendment filed as Exhibit 3.1 for the complete legal terms.
- Review the January 26, 2024 press release filed as Exhibit 99.1.
- Assess the reverse split’s effect on the market price, liquidity, and Nasdaq listing status of the common stock.